Neurology · 2020 · 169 citations · 23 references
MedicineNeurologyMovement DisordersNeuromuscular DisordersNeuropathologyMyasthenia GravisNeuromuscular Disorder PharmacotherapyNeuromuscular Junction DisordersJuvenile Myasthenia GravisLate-onset Myasthenia GravisMyasthenia Gravis Pharmacotherapy
OBJECTIVE: To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). METHODS: This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular Diseases (NMD-ES). All patients were >18 years of age at onset of MG and onset occurred between 2000 and 2016 in all cases. Patients were classified into 3 age subgroups: early-onset MG (age at onset <50 years), late-onset MG (onset ≥50 and <65 years), and very-late-onset MG (onset ≥65 years). Demographic, immunologic, clinical, and therapeutic data were reviewed. RESULTS: < 0.0001). CONCLUSIONS: Patients with MG are primarily ≥65 years of age with anti-AChR antibodies and no thymoma. Although patients with very-late-onset MG may present life-threatening events at onset, they achieve a good outcome with fewer immunosuppressants when diagnosed and treated properly.
23
Autoimmune Response to Acetylcholine Receptor
Jim Patrick, Jon Lindstrom · Science · 1973 · 1K citations
Medicine, Immunology, Neurology +13
Randomized Trial of Thymectomy in Myasthenia Gravis
Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · New England Journal of Medicine · 2016 · 905 citations · Full text
Medicine, Endocrinology, Surgery +12
Myasthenia gravis: recommendations for clinical research standards
Alfred Jaretzki, Richard J. Barohn, Raina M. Ernstoff et al. · The Annals of Thoracic Surgery · 2000 · 642 citations · Full text
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
Amelia Evoli · Brain · 2003 · 613 citations
Medicine, Immunology, Pathology +15